SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) March 15, 2004
Progenics Pharmaceuticals, Inc.
(Exact name of registrant as specified in its charter)
Delaware 000-23143 13-3379479
------------------------ ----------------- -------------------
(State or other jurisdiction (Commission (IRS Employer
of incorporation) File Number) Identification No.)
777 Old Saw Mill River Road, Tarrytown, New York 10591
--------------------------------------------------------------
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code (914) 789-2800
----------------------
------------------------------------------------------------
(Former name or former address, if changed since last report.)
Item 7. Financial Statements, Pro Forma Financial Information and Exhibits.
(c) Exhibits
EXHIBIT NUMBER DESCRIPTION
Exhibit 99.1 Press Release dated March 15, 2004 of the Company
announcing its results of operations for its fourth
quarter and for the year ended December 31, 2003 and
announcing an expansion of its senior management team
(filed herewith).
Item 12. Results of Operations and Financial Condition.
The Company furnishes its press release dated March 15, 2004, in which the
Company announces, among other things, its results of operations for its fourth
quarter and for the year ended December 31, 2003 and an expansion of its senior
management team. A copy of the press release is attached as Exhibit 99.1 to this
Current Report on Form 8-K.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
PROGENICS PHARMACEUTICALS, INC.
By: /s/ PHILIP K. YACHMETZ
-------------------------------------------
Philip K. Yachmetz
Vice President, General Counsel and Secretary
Date: March 15, 2004
--------------